G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
115 hedge funds and large institutions have $1.39B invested in G1 Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 47 increasing their positions, 21 reducing their positions, and 12 closing their positions.
167% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 12
124% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 21
39% more capital invested
Capital invested by funds: $998M → $1.39B (+$391M)
21% more funds holding
Funds holding: 95 → 115 (+20)
99% less call options, than puts
Call options by funds: $5K | Put options by funds: $675K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$29.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.1M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.76M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$6.27M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.25M |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
-$5.24M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.34M |
GTHX Hedge Fund Activity: Q3 2018 in Review
115 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2018, worth a combined $1.39B — up 39% from $998M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new GTHX positions and 12 closed out — a net gain of 20 holders — while 47 added to existing stakes and 21 trimmed.
The largest buyer was Vanguard Group, adding an estimated $40.5M. The largest seller was State Street, cutting an estimated $6.76M.
- 115 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2018, up from 95 in Q2 2018.
- Funds reported $1.39B of G1 Therapeutics, Inc. Common Stock stock for Q3 2018, up 39% quarter-over-quarter.
- 32 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2018 and 12 closed out, a net change of +20 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2018 was Vanguard Group, an estimated $40.5M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2018 was State Street, an estimated $6.76M sold.
Based on aggregated 13F filings for Q3 2018.